Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
INDV-2000 + buprenorphine + naloxone
- Development stage
- Unknown
- Lead developer
- Indivior
- Modality
- Small Molecules
- Administration
- Oral, Sublingual, Buccal
01
Overview
INDV-2000 + buprenorphine + naloxone is a combination regimen under clinical investigation for the treatment of **opioid use disorder**. INDV-2000 is a potent and selective oral antagonist for the orexin-1 receptor (OX1R), acting as a non-opioid agent that targets the orexin pathway which plays a key role in the neurobiology of substance use disorders[1][3][5]. Buprenorphine is a partial opioid agonist at mu-opioid receptors, managing withdrawal and cravings while exerting a ceiling effect to reduce risk of overdose[2][4][6]. Naloxone is a pure opioid receptor antagonist (primarily mu-opioid) added to deter intravenous misuse and reverse opioid effects in case of overdose[2][4][6]. In clinical protocols, subjects may be stabilized on buprenorphine/naloxone, then treated with INDV-2000 in combination during the withdrawal/transition phase[5]. The combination is being developed and tested by Indivior specifically to assess safety and efficacy in individuals with opioid use disorder.
- Brand names
- Suboxone
- Other names
- buprenorphine + naloxonebuprenorphine-naloxoneINDV-2000 combinationINDV2000 combinationINDV 2000 combination
02
Targets
NOP (Nociceptin/orphanin FQ peptide receptor)HCRTR1 (Orexin/hypocretin receptor type 1)MOR (Mu opioid receptor)DOR (Opioid Receptor Delta 1)KOR (Kappa opioid receptor)
Beyond the preview
Go deeper on INDV-2000 + buprenorphine + naloxone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on INDV-2000 + buprenorphine + naloxone.